Abstract:The Dearing isolate of Mammalian orthoreovirus (T3D) is a prominent model of virus-host relationships and a candidate oncolytic virotherapy. Closely related laboratory strains of T3D, originating from the same ancestral T3D isolate, were recently found to exhibit significantly different oncolytic properties. Specifically, the T3DPL strain had faster replication kinetics in a panel of cancer cells and improved tumor regression in an in vivo melanoma model, relative to T3DTD. In this study, we discover that T3DPL and T3DTD also differentially activate host signalling pathways and downstream gene transcription. At equivalent infectious dose, T3DTD induces higher IRF3 phosphorylation and expression of type I IFNs and IFN-stimulated genes (ISGs) than T3DPL. Using mono-reassortants with intermediate replication kinetics and pharmacological inhibitors of reovirus replication, IFN responses were found to inversely correlate with kinetics of virus replication. In other words, slow-replicating T3D strains induce more IFN signalling than fast-replicating T3D strains. Paradoxically, during co-infections by T3DPL and T3DTD, there was still high IRF3 phosphorylation indicating a phenodominant effect by the slow-replicating T3DTD. Using silencing and knock-out of RIG-I to impede IFN, we found that IFN induction does not affect the first round of reovirus replication but does prevent cell-cell spread in a paracrine fashion. Accordingly, during co-infections, T3DPL continues to replicate robustly despite activation of IFN by T3DTD. Using gene expression analysis, we discovered that reovirus can also induce a subset of genes in a RIG-I and IFN-independent manner; these genes were induced more by T3DPL than T3DTD. Polymorphisms in reovirus σ3 viral protein were found to control activation of RIG-I/ IFN-independent genes. Altogether, the study reveals that single amino acid polymorphisms in reovirus genomes can have large impact on host gene expression, by both changing replication kinetics and by modifying viral protein activity, such that two closely related T3D strains can induce opposite cytokine landscapes.Mammalian orthoreovirus serotype 3 Dearing (T3D reovirus) is being explored as a cancer therapy. Laboratories worldwide use independent strains of T3D, that we previously demonstrated to have different oncolytic potency in vivo; but what impact does the small genomic diversity between T3D reovirus strains have on host responses? Herein, we discover that host response varies significantly between T3D lab strains; for example, the T3DTD strain causes higher IFN induction and expression of IFN-dependent cytokines, while the T3DPL strain conversely causes higher induction of RIG-I/IFN-independent genes and cytokines. Mechanistically, higher IFN signalling is caused by gene polymorphisms in S4, M1, or L3 reovirus genes that decelerate virus replication kinetics, while higher non-IFN gene induction is attributed to polymorphisms in the reovirus S4 gene-encoded dsRNA binding protein σ3. Unexpectedly, IFN induction by the slow T3DTD strain phenodominated during T3DTD/ T3DPL coinfections, suggesting distinct behaviours of incoming virions. Moreover, IFN responses had minimal effects on the first round of reovirus replication. Overall, the data reveals how single amino acid changes can profoundly and even inversely affect host cell response to reovirus. The prospect of manipulating reovirus replication kinetics and σ3 could help optimize the host response for greatest oncolytic and immunotherapeutic potency.

Figure S3 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Figure S4 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Figure S5 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Figure S6 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Intertumoral Differences Dictate the Outcome of TGF-beta Blockade on the Efficacy of Viro-Immunotherapy

Figure S1 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Table TS1 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Table TS2 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles

Immune characterization of metastatic colorectal cancer patients post reovirus administration

Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity

Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer

Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systems

589 Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion

Immunotherapeutic Potential of TGF-beta Inhibition and Oncolytic Viruses

Neutralizing antibodies impair the oncolytic efficacy of reovirus but permit effective combination with T cell–based immunotherapies

Effects Of Transforming Growth Factor-Alpha (Tgf-Alpha) In Vitro And In Vivo On Reovirus Replication

Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model

Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity

Closely related reovirus lab strains induce opposite expression of RIG-I/IFN-dependent versus -independent host genes, via mechanisms of slow replication versus polymorphisms in dsRNA binding σ3 respectively